Scopus
YÖKSİS DOI Eşleşti
SJR Q2
Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Clinical Lymphoma Myeloma and Leukemia · Ağustos 2016
YÖKSİS Kayıtları
Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Clinical Lymphoma Myeloma and Leukemia · 2016 SCI-Expanded
Prof. Dr. SÜLEYMAN BALDANE →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
2016 ISSN: 21522650 SCI-Expanded
Prof. Dr. SÜLEYMAN BALDANE →
Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia
2019 ISSN: 2152-2650 SCI-Expanded
Prof. Dr. RAFİYE ÇİFTÇİLER →
Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia
2019 ISSN: 2152-2650 SCI-Expanded
Prof. Dr. RAFİYE ÇİFTÇİLER →
Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia
2019 ISSN: 2152-2650 SCI-Expanded Q3
Prof. Dr. RAFİYE ÇİFTÇİLER →
A case of Burkitt lymphoma re presenting as periportal hepatic and multiple organ infiltration
2008 ISSN: 2152-2650 SCI-Expanded
Prof. Dr. YAVUZ KÖKSAL →
Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
2023 ISSN: 2152-2650 SCI-Expanded Q3
Prof. Dr. RAFİYE ÇİFTÇİLER →
Makale Bilgileri
ISSN21522650
Yayın TarihiAğustos 2016
Cilt / Sayfa16 · S10-S18
Scopus ID2-s2.0-84992051077
Özet
Transfusional iron overload remains a serious problem in alloHSCT setting. Liver is among the most common organs that iron accumulate. The degree of hepatic iron content might be associated with poorer survival in alloHSCT recipients. Aim Iron overload results in increased infection, venous-oclusive disease and hepatic dysfunction in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. Liver is one of the most common sites of iron overload. Patients and Methods A total of 50 alloHSCT recipients that underwent liver biopsy in Erciyes Stem Cell Transplantation Hospital, Erciyes University, between 2004 and 2011 were enrolled in the study. The liver biopsy specimens have been obtained from the archives of Erciyes University, Department of Pathology and stainned for iron content. Results The mean age was found 34 ± 11 years. For median overall survival (OS); 53 months (min-max: 41-65) in patients with grade 0, 55 months (min-max: 47-64) in patients with grade 1, in patients with grade 2 patients 25.4 months (11.5-39.4 ), grade 3 patients 29.3 months (min-max: 12.3-46.3) and grade 4 patients 2.6 months (min-max: 2.0-3.3). Overall survival was correlated with the degree of liver iron content and it was statistically significant in Kaplan-Meier analysis (P < .001). Disease-free survival was found (DFS); grade 0 patients 47.1 months (min-max: 32.0-62.0), grade 1 patients 36.9 months (min-max: 21.0-65.0), grade 2 patients 23.5 months (min-max: 12.0-59.0), grade 3 patients 27.4 months (min-max: 5.3-59.3) and grade 4 patients 2.6 months (min-max: 2.0-3.0). For DFS; it was negatively correlated with the degree of liver iron content nevertheless; it was not was statistically significant in Kaplan-Meier analysis (P = .093).Hepatic iron overload might be associated with poor survival in patients with transfusional iron overload that underwent alloHSCT. Conclusion Hepatic iron content might be associated with poorer prognosis in patients with iron overload that underwent alloHSCT.
Yazarlar (8)
1
Serdar Sivgin
2
Süleyman Baldane
3
Kemal Deniz
4
Gokmen Zararsiz
5
Leylagul Kaynar
6
Mustafa Cetin
7
Ali Unal
8
Bulent Eser
Anahtar Kelimeler
Allogeneic hematopoietic stem cell transplantation
Ferritin
Hepatic iron overload
Survival
Kurumlar
Erciyes Üniversitesi
Kayseri Turkey
Scimago Dergi (ISSN Eşleşmesi)
Clinical Lymphoma, Myeloma and Leukemia
Q2
SJR Skoru0,615
H-Index71
YayıncıElsevier Inc.
ÜlkeUnited States
Hematology (Q2)
Cancer Research (Q3)
Oncology (Q3)
Metrikler
9
Atıf
8
Yazar
4
Anahtar Kelime